Neurocrine’s Crenessity enables glucocorticoid dose reduction in CAH study

Neurocrine (NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalyst Adult study demonstrating sustained, substantial reductions in glucocorticoid, or GC, doses in adults with classic congenital adrenal hyperplasia treated with Crenessity – crinecerfont -, with approximately 70% of patients achieving GC doses within the physiologic range. These data were presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas. Chronic exposure to supraphysiologic GC doses is associated with cardiometabolic comorbidities, bone density reductions, mental health issues and other long-term health risks that contribute to the cumulative treatment burden faced by patients over their lifetimes. At Month 24 of the study, 69% of 149 participants achieved a physiologic GC dose, with many participants eliminating nonphysiologic GC types. Of 20 participants originally taking dexamethasone, 75% switched to a dexamethasone-free regimen, while 62% of 60 patients taking more than two doses of hydrocortisone per day were able to eliminate a dose outright. GC dose reductions and regimen changes were achieved without worsening androstenedione levels relative to baseline, indicating that lowering the GC dose was not achieved at the expense of androgen control. Long-term treatment with Crenessity was generally well tolerated, with more than 80% study retention at two years and no new safety signals observed.